Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the first part of this study or the dose escalation portion of the study is to
determine what dose of BKM120 and Abraxane is safe to give when the two drugs are used at the
same time in patients who are diagnosed with a solid cancer. A solid cancer is a cancer that
does not involve the blood, bone marrow or lymph nodes. Dose escalation determines the least
toxic and most effect dose of this drug combination for treatment. Once this dose is
established, it will be used for the dose expansion phase of the study where we will
determine the effect of BKM120 and Abraxane in women diagnosed with a recurrent endometrial
or ovarian cancer. We will see whether the combination of both drugs improves the response
and survival of patients treated on the two drug regimen. Also we will try to find out
whether there are changes in tumors that can help us determine what patients are more likely
to respond to BKM120 and Abraxane.
Phase:
Phase 1
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
National Cancer Institute (NCI) Rutgers Cancer Institute of New Jersey